Φορτώνει......

Discontinuation due to immune‐related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non‐small cell lung cancer

BACKGROUND: Immune‐related adverse events (irAEs) should be anticipated with treatment by immune checkpoint inhibitors (ICIs). Although the relationship between irAEs and efficacy of ICI has been reported, it has not yet been clarified whether the benefit from ICI outweighs the low frequency of proc...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Thorac Cancer
Κύριοι συγγραφείς: Komiya, Kazutoshi, Nakamura, Tomomi, Abe, Tomonori, Ogusu, Shinsuke, Nakashima, Chiho, Takahashi, Koichiro, Kimura, Shinya, Sueoka‐Aragane, Naoko
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: John Wiley & Sons Australia, Ltd 2019
Θέματα:
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6718019/
https://ncbi.nlm.nih.gov/pubmed/31328416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13149
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!